Journal ofthe Royal Society ofMedicine Volume 71 July 1978 teaching hospitals, the loss of whose skills would be an irreparable loss to the NHS; the DGHs with their vital acute function (not forgetting a mental illness function too); and the community hospital where the patient, after the acute phase of his illness (or when in need of nursing care), can complete his recovery in the cheaper and frequently more pleasant ambience where his family physician can once more resume his primary care with relatives or friends close by.
Dr Paulley argues for more involvement of the local consumers in influencing development. I suspect he means both public and providers alike. But are not community health councils on the one hand, and the numerous advisory committees at all levels (which the medical profession actively sought) and the 'management team' mechanism for decision-making on the other, the answers to his argument? JOHN DONNE 28 April 1978 From Dr A F Tuxford Department of Bacteriology & Virology, University ofManchester, Manchester M13 9PT Dear Sir, I have read the recent correspondence with some interest and feel that perhaps undue. emphasis has been placed on the provision of medical care as the criterion for hospital admission.
The person who becomes ill not only has a condition which requires diagnosis and treatment, but also may become unable to continue his or her routine for daily life. In severe illness he or she may return to a state of physical dependence resembling that of childhood. Although the doctor deals primarily with the illness, the nurse is concerned with both aspects, and the greater part of the nurse's time may be devoted to providing maternal-type care. This caring function in minor illness previously was usually provided by other members of the household, but with the increase in the numbers of single-person or single-parent households and working wives, this has frequently become impossible. The result is increased admission to hospital, since the domiciliary facilities are inadequate.
Patients who are not very ill like to have plenty of visitors and do not require the provision of highly-complex equipment or highly-trained staff, etc, for their treatment. This suggests a need for local hostel-type accommodation, which might be run in association with local general practitioner hospitals. Alternatively, consideration should be given to the need for provision of domiciliary services,e.g. meals on wheels three times daily, and a temporary two-way radio, which would enable patients to stay in their own homes, presumably at less cost to the National Health Service. This service would not exclude the need for both district general or teaching hospitals, but should require the provision of fewer beds for certain specialties. The implementation of such schemes would, of course, place a heavier load on the family doctor, but would increase the variety and interest of his/her work, providing better job satisfaction. Journal, p 324) , to cover in depth all aspects of this subject, especially the somewhat confusing and evolving system of regulation. It is necessary to note that when the United Kingdom became a member of the European Economic Community (EEC) on I January 1973,Council Directive 65/65 setting out a common basis for dealing with the licensing of medicinal products had already been adopted. Two complementary Directives, 75/3l8 and 75/3l9, were adopted in May 1975. All three Directives are binding on member states. Directive 75/318 is generally known as the 'standards and protocol' Directive, and it sets out the type of information required to license a new medicinal product. It covers minimum standards for chemistry, pharmacy, pharmacology, toxicology and clinical trials.
The 75/319 Directive established a Committee for Proprietary Medicinal Products (CPMP), with each member state represented by an official concerned with applications in his own country. In simple terms, this Committee can be regarded as the Committee on Safety of Medicines of the EEC. The CPMP has set up two working parties which were given the task to draw up guidelines on toxicity requirements and efficacyrequirements for new drugs. Those guidelines have already been promulgated and show a degree of flexibility of approach which is reassuring. Another advisory body with a broad policy remit in the field of medicinal products is the Pharmaceutical Committee. It is this Committee which will consider revisions to existing Directives and also any proposals for new Directives. This body is analogous to the Medicines Commission. These Directives could limit the scope for flexibility of member states' 'drug regulatory authorities'. On
